2/5
04:10 pm
eldn
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
High
Report
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
1/23
07:00 am
eldn
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
Medium
Report
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
1/8
04:56 pm
eldn
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook [Yahoo! Finance]
Low
Report
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook [Yahoo! Finance]
1/8
04:05 pm
eldn
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Neutral
Report
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
12/31
08:07 am
eldn
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
Neutral
Report
The End of Shots? 5 Biotech Stocks Rethinking Diabetes
12/2
03:41 pm
eldn
Eledon Pharmaceuticals (NASDAQ:ELDN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Eledon Pharmaceuticals (NASDAQ:ELDN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/1
07:13 am
eldn
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]
Medium
Report
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]
12/1
07:00 am
eldn
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
Medium
Report
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
11/18
04:05 pm
eldn
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
Medium
Report
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
11/18
09:14 am
eldn
Eledon Pharmaceuticals (NASDAQ:ELDN) had its price target lowered by analysts at Guggenheim from $9.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Eledon Pharmaceuticals (NASDAQ:ELDN) had its price target lowered by analysts at Guggenheim from $9.00 to $8.00. They now have a "buy" rating on the stock.
11/17
01:19 pm
eldn
Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
Low
Report
Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]
11/14
05:58 pm
eldn
Eledon Pharmaceuticals GAAP EPS of -$0.21 [Seeking Alpha]
High
Report
Eledon Pharmaceuticals GAAP EPS of -$0.21 [Seeking Alpha]
11/14
05:26 pm
eldn
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results [Yahoo! Finance]
11/14
05:00 pm
eldn
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Medium
Report
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results